Arslan, ZGökyayla, EBilaç, C2025-04-102025-04-101819-7124http://hdl.handle.net/20.500.14701/33548Studies have shown that neutrophil/lymphocyte ratio [NLR], platelet/lymphocyte ratio [PLR] and mean platelet volume [MPV] can be used in CSU as a marker of inflammation level and treatment response. In our study, we aimed to compare NLR, PLR and MPV values between the control group and pre-treatment patient group. In addition, our second aim was to investigate changes with antihistamine treatment and omalizumab treatment in the CSU patient group when compared with the control group. 146 patients who applied to Dermatology and Venereal Diseases outpatient clinic, with a diagnosis of chronic spontaneous urticaria, using antihistamine or omalizumab were included in the study. The neutrophil and NLR values of the antihistamine and omalizumab treatment group with CSU diagnosis were found to be significantly higher than the pre-treatment control group, but there was no significant difference between each other. Platelet count was found higher and MPV value was found lower in omalizumab group when compared with the control group. In the omalizumab group, a significant decrease in neutrophil count and platelet count was measured at 3rd months. Neutrophil count, platelet count, NLR values were significantly high and MPV values were found significantly low when compared with the control group, therefore these values could be used to determine disease activity. A significant decrease in neutrophil count and platelet count was detected in the omalizumab group post-treatment. By the reason of its anti-IgE effect, omalizumab could show its anti-inflammatory effect by reducing the neutrophil count and platelet count.EnglishArticle1819-7132